Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alfa-2a: review decison - October 2011
Review of TA96; Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B, TA154; Telbivudine for the treatment of chronic hepatitis B, TA153; Entecavir for the treatment of chronic hepatitis B and TA173; Tenofovir disoproxil fumarate for the treatment of hepatitis B
NICE has been asked to develop a clinical guideline and quality standard on the diagnosis and management of hepatitis B. These projects overlap with the technology appraisals listed above. It was therefore proposed that the technology appraisals be included in the guideline as follows:
- TA153, TA154, TA173 and recommendation 1.1 of TA96 – These recommendations will be incorporated, verbatim, into the clinical guideline. The technology appraisals will be moved to the static list and will remain extant when the guideline is published. This has the consequence of preserving the funding direction for TA153, TA173 and recommendation 1.1 of TA96. The guideline will contextualise this guidance by considering the place of the recommended options within treatment sequences and combination drug regimens.
- Recommendations 1.2–1.4 of TA96 – These recommendations will be updated by the clinical guideline and the technology appraisal recommendations will be withdrawn when the guideline is published.
During consultation, the majority of comments received by the Institute agreed with the proposals put forward. After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposals.
This page was last updated: 07 January 2013